About Us
General Biologicals Corporation (GBC) was founded in 1984 and is a Taiwan-based diagnostics company with more than four decades of experience in in vitro diagnostics. From immunodiagnostics and molecular diagnostics to automated testing and liquid biopsy, GBC continues to advance its capabilities in precision diagnostics.
By integrating R&D, manufacturing, diagnostic platforms and clinical services, GBC serves healthcare institutions and partners across more than 40 countries.
Corporate Governance
Organization
Director
Director | CHLITINA Holding Limited
Chairman, GB Pharma
Chairman, Andra Capital | Adjunct Professor, National Taiwan University | Independent Director of several publicly listed companies
Senior Finance Director, CHLITINA | Chief Financial Officer, CHLITINA (China)
Independent Director
Adjunct Professor, National Yang Ming Chiao Tung University
Adjunct Professor, National Taipei University
Director, GlycoNex Inc.
Independent Director, PRIT Biotech Co., Ltd.
President, Glonova Therapeutics Co., Ltd.
Consultant, T-TOP Clinical Research Co., Ltd.
Director, Yolk Partners Co., Ltd.
Independent Director, Weikeng Industrial Co., Ltd.
Independent Director, TSH Biopharm Corporation Ltd.
FAQ
GBC develops, manufactures and markets in vitro diagnostic products and diagnostic systems across immunodiagnostics, molecular diagnostics, automated testing and precision oncology and liquid biopsy. The company also provides clinical laboratory and IVD development and manufacturing services through its broader capabilities and Group businesses.
GBC’s financial reports are available in the Financial Information section of this website and through Taiwan’s Market Observation Post System (MOPS). market/exchange and stock code 4117.
https://emops.twse.com.tw/server-java/t58query
Chairman, CurieMed Corporation | Chairman, Danner Lab Inc. | Chairman, Pacgen Life Science